These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 20859794

  • 1. Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds.
    Francis SH, Sekhar KR, Ke H, Corbin JD.
    Handb Exp Pharmacol; 2011; (200):93-133. PubMed ID: 20859794
    [Abstract] [Full Text] [Related]

  • 2. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H.
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [Abstract] [Full Text] [Related]

  • 3. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A, Blokland A.
    Eur J Pharmacol; 2007 Mar 08; 558(1-3):107-12. PubMed ID: 17207788
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y, Chackalamannil S, Czarniecki M, Tsai H, Vaccaro H, Cleven R, Cook J, Fawzi A, Watkins R, Zhang H.
    J Med Chem; 1997 Dec 19; 40(26):4372-7. PubMed ID: 9435906
    [Abstract] [Full Text] [Related]

  • 5. Phosphodiesterase inhibitors.
    Boswell-Smith V, Spina D, Page CP.
    Br J Pharmacol; 2006 Jan 19; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
    [Abstract] [Full Text] [Related]

  • 6. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
    Corbin JD, Beasley A, Blount MA, Francis SH.
    Neurochem Int; 2004 Nov 19; 45(6):859-63. PubMed ID: 15312980
    [Abstract] [Full Text] [Related]

  • 7. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
    Truss MC, Uckert S, Stief CG, Schulz-Knappe P, Hess R, Forssmann WG, Jonas U.
    Urology; 1995 May 19; 45(5):893-901. PubMed ID: 7747383
    [Abstract] [Full Text] [Related]

  • 8. Potency, selectivity, and consequences of nonselectivity of PDE inhibition.
    Bischoff E.
    Int J Impot Res; 2004 Jun 19; 16 Suppl 1():S11-4. PubMed ID: 15224129
    [Abstract] [Full Text] [Related]

  • 9. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: effects on airways smooth muscle.
    Raeburn D, Advenier C.
    Int J Biochem Cell Biol; 1995 Jan 19; 27(1):29-37. PubMed ID: 7757880
    [Abstract] [Full Text] [Related]

  • 10. Methylxanthine inhibitors of phosphodiesterases.
    Wells JN, Miller JR.
    Methods Enzymol; 1988 Jan 19; 159():489-96. PubMed ID: 2457788
    [No Abstract] [Full Text] [Related]

  • 11. Phosphodiesterase inhibitors as tools in cyclic nucleotide research: a precautionary comment.
    Wells JN, Kramer GL.
    Mol Cell Endocrinol; 1981 Jul 19; 23(1):1-9. PubMed ID: 6167475
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
    Ahn HS, Bercovici A, Boykow G, Bronnenkant A, Chackalamannil S, Chow J, Cleven R, Cook J, Czarniecki M, Domalski C, Fawzi A, Green M, Gündes A, Ho G, Laudicina M, Lindo N, Ma K, Manna M, McKittrick B, Mirzai B, Nechuta T, Neustadt B, Puchalski C, Pula K, Zhang H.
    J Med Chem; 1997 Jul 04; 40(14):2196-210. PubMed ID: 9216839
    [Abstract] [Full Text] [Related]

  • 17. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
    Mushlin P, Boerth RC, Wells JN.
    Mol Pharmacol; 1981 Jul 04; 20(1):179-89. PubMed ID: 6270531
    [No Abstract] [Full Text] [Related]

  • 18. PDE inhibitors: a new approach to treat metabolic syndrome?
    Lugnier C.
    Curr Opin Pharmacol; 2011 Dec 04; 11(6):698-706. PubMed ID: 22018840
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
    Ilien B, Ruckstuhl M, Landry Y.
    J Pharmacol; 1982 Dec 04; 13(2):307-16. PubMed ID: 6285085
    [Abstract] [Full Text] [Related]

  • 20. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
    Torphy TJ, Cieslinski LB.
    Mol Pharmacol; 1990 Feb 04; 37(2):206-14. PubMed ID: 2154670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.